Opdivo 40 mg (Nivolumab 40 mg) by Bristol Myers Squibb.
Indications: Melanoma, NSCLC, renal cell carcinoma, classical Hodgkin lymphoma, head and neck, urothelial, oesophageal, gastric and colorectal cancers (per SmPC).
Administration: Intravenous infusion, e.g. 240 mg every 2 weeks or 480 mg every 4 weeks.
Storage: Store in a refrigerator at 2–8 °C. Do not freeze. Keep in the outer carton to protect from light.
Prescription-only medicine (POM). Supplied against a valid prescription / to licensed healthcare professionals only.
| Manufacturer | Bristol Myers Squibb |
| Active ingredient | Nivolumab 40 mg (4 ml, 10 mg/ml) — anti-PD-1 monoclonal antibody. |
| Strength & pack | 1 vial. |
| Form | Concentrate for solution for infusion |
| Storage | Store in a refrigerator at 2–8 °C. Do not freeze. Keep in the outer carton to protect from light. |
| Regulatory status | Prescription-only medicine (POM). Supplied against a valid prescription / to licensed healthcare professionals only. |